Market Context — Why This Technology, Why Now

The global shift towards advanced in-vitro models for drug development and personalized medicine is accelerating, driven by the need for more accurate disease representations and reduced reliance on animal testing. Concurrently, the burgeoning cellular agriculture sector demands scalable and precise tissue engineering solutions for sustainable food production. This technology directly addresses these trends by offering a highly reproducible and efficient method for 3D tissue manufacturing, poised to capture value in these rapidly expanding markets.

Key Competitive Advantages
01

Standardizes Manufacturing Process and Enhances Reproducibility: This technology combines a predetermined protruding part and multiple anchor parts to achieve highly reproducible artificial 3D tissue manufacturing, unlike conventional non-uniform culture methods.

02

Significantly Simplifies Manufacturing Process: The anchor part configuration promotes cell self-organization without external contractile forces, potentially improving operational efficiency by ~30% by reducing skilled labor requirements.

03

Accelerates Research and Development Lead Time: With only three prior art documents, this technology demonstrates high market originality, enabling early competitive differentiation and market leadership.

Market Opportunity
Regenerative Medicine
$25B–$30B globally (AI est.)
Growing demand for treating tissue damage and organ failure in aging societies, making this a foundational technology for developing cell sheets and mini-organs.
Regenerative medicine biotechs Pharmaceutical companies developing cell therapies Medical device manufacturers for tissue engineering
Drug Discovery Screening
$5B–$5.5B globally (AI est.)
Expanding demand for high-precision disease models that mimic human physiological functions to improve drug development success rates and shorten development timelines.
Large pharmaceutical R&D divisions Contract Research Organizations (CROs) Biotech firms specializing in in-vitro models
Cellular Agriculture & Cultured Food
$1B–$1.5B globally (AI est.)
Growing interest in cellular agriculture, such as cultured meat and fish, driven by environmental sustainability and food security concerns, where tissue construction technology is key.
Cultured meat/seafood startups Food technology companies Ingredient suppliers for alternative proteins
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent is considered a robust and independently established right, having overcome examiner objections with only three prior art documents. It protects the specific physical configuration of the apparatus for manufacturing artificial 3D tissues, including the protruding part and multiple anchor parts. The strong claims and successful prosecution history suggest a low risk of invalidation, providing a solid foundation for business development.

Competitive White Space

Adjacent white space could involve advanced bioreactor designs for large-scale production, automated cell seeding and harvesting systems, or novel biomaterials for scaffold-free tissue engineering beyond the current apparatus configuration.

Economic Impact
~$65K/year estimated cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Operating in a lab with ~$335K (AI est.) annual personnel costs, this technology could reduce labor costs by ~15% (0.15 × ~$335K = ~$50K (AI est.)) and material/reagent costs by ~10% (0.10 × ~$135K = ~$15K (AI est.)) due to reduced failure rates. Total estimated annual savings: ~$65K (AI est.).

Speed to Market
5× faster than in-house development
This technology significantly shortens the basic research phase because its specific apparatus configuration and operational principles are clearly defined in the patent claims and drawings. As the University of Tokyo holds the rights, the technology's reliability is high, and validated data is likely available. This could reduce development time by approximately 4.0 years compared to in-house development.
Competitive Positioning

X: Tissue Structure Control Precision
Y: Manufacturing Efficiency & Reproducibility

Business Models & Applications
🔬 Research Contract Services
Provide artificial 3D tissue models, manufactured using this technology, as research tools for drug screening and disease mechanism elucidation to pharmaceutical companies and research institutions. Contributes to efficient compound evaluation with high reproducibility.
🏭 Apparatus & Technology Licensing
Sell or license the artificial 3D tissue manufacturing apparatus, based on this technology, to universities, research institutions, and biotech ventures. Adopting companies gain a customizable platform for in-house use.
🩹 Regenerative Medicine Product Development
Offer contract manufacturing of custom-made 3D tissues for wound repair and tissue regeneration using patient-derived cells in the regenerative medicine sector. This could accelerate personalized medicine.
Adjacent Application Opportunities
💊 Pharmaceutical Development
Disease Models for Personalized Medicine
This technology could efficiently produce 'organ-on-chip' models that replicate specific disease responses or drug reactions. This offers rapid and high-precision evaluation of drug efficacy and side effects, streamlining drug development pipelines.
🥩 Food Production
Enhancing Cultured Food Quality
In cellular agriculture for cultured meat and fish, this technology could be applied to manufacture 3D tissues with optimized texture and nutritional value. It has the potential to combine various cell types to reproduce structures closer to natural meat.
💉 Medical Devices
Developing Biocompatible Materials
For developing biocompatible medical implants and biomaterials, this technology could organize specific cells to enhance in-vivo compatibility. This could contribute to longer-term functional maintenance of medical devices.
Integration Roadmap — Estimated 18-Month Deployment
Phase 1: PoC & Prototype Development
Duration: 3 months
Conduct basic functional verification and initial design tailored to the desired tissue characteristics for the adopting company. Confirm technical efficacy through proof-of-concept.
Phase 2: Pilot Operation & Validation
Duration: 6 months
Based on the initial design, conduct device prototyping and small-scale validation experiments. Evaluate compatibility with the adopting company's existing research processes and workflows, making necessary adjustments.
Phase 3: Full-Scale Implementation & Optimization
Duration: 9 months
Based on pilot validation results, optimize design for mass production and large-scale deployment. Establish final quality control systems and commence full operational use.
Technical Feasibility
This technology induces 3D tissue formation through physical components—a protruding part and anchor parts—eliminating the need for complex software development or extensive facility modifications. The configuration described in the patent claims, specifically the 'protruding part extending in a predetermined direction' and 'multiple anchor parts located radially on both sides of the protrusion,' suggests it could be designed and integrated as a module compatible with existing culture incubators and cell processing equipment, indicating low technical barriers to adoption.
Success Scenario
Implementing this technology could enable the stable manufacturing of artificial 3D tissues that are significantly more uniform and reproducible than conventional methods. This may improve evaluation accuracy in drug screening, potentially shortening new drug development timelines by up to 20%. Furthermore, establishing human-like disease models could contribute to reducing animal testing and enhancing research ethics.
Patent Record
APPLICATION NO.
特願2020-188841
REGISTRATION NO.
7627020
FILING DATE
2020年11月12日
GRANT DATE
2025年01月28日
EXPIRATION DATE
2040年11月12日
PATENT HOLDER
国立大学法人　東京大学
Examination History
2023年10月19日
出願審査請求書
2024年07月30日
拒絶理由通知書
2024年09月20日
意見書
2024年09月20日
手続補正書（自発・内容）
2025年01月07日
特許査定